Chimerix Investor Conference Presentation Deck
✓
●
●
25
H3 K27M-mutant DMG is a grade IV by WHO
FDA has acknowledged available therapy is
palliative
Often not possible to resect
Recurrence inevitable after first-line radiation
-
Recurrent Glioma Remains a High Unmet Need
-
Chemotherapy ineffective; objective responses
by RANO-HGG have not been reported
Survival in grade II-IV recurrent glioma
reported to be 27.5% at 12 months¹ and
6.4% at 24 months²
Survival in pediatric recurrent H3 K27M DMG
reported to be 0% at 24 months³
Survival in ONC201-treated recurrent H3
K27M DMG was 57% OS at 12 months and
35% at 24 months
Survival Probability (%)
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Recurrent glioma historic survival
0.6
Coocoon
27.5%
OS at 12 Months¹
Survival Probability (%)
0.5
Grade II-III Glioma
0.4
0.3
0.2
0.1
0.0
6.4%
OS at 24 Months²
GBM (Grade IV)
1. Data collected from 15 literature sources since 2010 with trial arms size >30 pts each reporting data on 1816 pts with recurrent, unstratified disease.
2. 10 literature sources that describes OS with 1279 patients
3. Koschmann et al, 2020; DOI:10.21203/rs.3.rs-69706/v1
O 2021 Chimerix, IncView entire presentation